MLYS (Mineralys Therapeutics) Accounts Receivable : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mineralys Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Mineralys Therapeutics's accounts receivables for the quarter that ended in Dec. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Mineralys Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $3.68.

Mineralys Therapeutics Accounts Receivable Historical Data

The historical data trend for Mineralys Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mineralys Therapeutics Accounts Receivable Chart

Mineralys Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Receivable

Mineralys Therapeutics Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Receivable	Get a 7-Day Free Trial									-	-	-	-	-

Mineralys Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Mineralys Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Mineralys Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Mineralys Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Mineralys Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(198.187	+	0.75 * 0	+	0.5 * 0	-	14.646
-	0	-	0)	/	49.822
=	3.68

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Mineralys Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Mineralys Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Mineralys Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mineralys Therapeutics Inc (NAS:MLYS) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087

Website

https://mineralystx.com

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Executives

David Malcom Rodman	officer: Chief Medical Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Jon Congleton	director, officer: Chief Executive Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Adam Scott Levy	officer: CFO, Chief Bus. Off. and Secy.	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Srinivas Akkaraju	director, 10 percent owner	565 EVERETT AVENUE, PALO ALTO CA 94301
Catalys Pacific Fund, Lp	10 percent owner	301 9-19 HACHIYAMA, SHIBUYA, TOKYO M0 150-0035
Glenn Sblendorio	director	3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Hbm Healthcare Investments (cayman) Ltd.	10 percent owner	GOVERNORS SQUARE, 23 LIME TREE BAY AVE.,, PO BOX 30852, GRAND CAYMAN E9 KY1-1204
Olivier Litzka	director	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Takeshi Takahashi	director	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Brian Taylor Slingsby	director, 10 percent owner	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Ra Capital Nexus Fund Iii, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Samsara Biocapital, L.p.	10 percent owner	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Alexander Asam	director	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361